Piper Sandler raises Masimo (NASDAQ:MASI) price target to $150.00

Masimo (NASDAQ:MASI – Get a rating) had its price target raised by analysts at Piper Sandler from $135.00 to $150.00 in a research report released Friday to clients and investors, reports The Fly. Piper Sandler’s price target indicates a potential upside of 5.32% from the company’s current price.

A number of other brokerages also weighed in on MASI. Wolfe Research upgraded Masimo from a “peer performance” rating to an “outperform” rating and set a target price of $165.00 for the company in a Thursday, September 15 research report. Needham & Company LLC raised its price target on Masimo shares from $163.00 to $179.00 and gave the company a “buy” rating in a Wednesday, August 10 research report. Stifel Nicolaus raised his price target on Masimo from $162.00 to $172.00 and gave the stock a “buy” rating in a Monday, September 12 research note. StockNews.com upgraded Masimo’s shares from a “buy” rating to a “hold” rating in a Wednesday, Aug. 10 research note. Finally, Loop Capital launched coverage on Masimo in a Tuesday, September 13 report. They issued a “buy” rating and a price target of $206.00 for the company. Three equity research analysts gave the stock a hold rating and five gave the company a buy rating. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $194.50.

Masimo shares down 3.9%

NASDAQ:MASI shares opened at $142.42 on Friday. The company has a market capitalization of $7.48 billion, a price/earnings ratio of 42.90 and a beta of 0.96. Masimo has a 12-month low of $112.07 and a 12-month high of $305.21. The company has a current ratio of 2.10, a quick ratio of 1.28 and a debt ratio of 0.77. The company has a 50-day moving average price of $148.89 and a 200-day moving average price of $141.21.

Masimo Inc (NASDAQ:MASI – Get Rating) last released quarterly earnings data on Tuesday, August 9. The medical equipment supplier reported earnings per share (EPS) of $1.35 for the quarter, beating the consensus estimate of $1.19 by $0.16. Masimo had a return on equity of 17.39% and a net margin of 12.68%. The company posted revenue of $565.30 million in the quarter, compared to analyst estimates of $540.56 million. During the same period last year, the company achieved EPS of $0.94. The company’s revenue for the quarter increased 87.9% year over year. As a group, stock research analysts expect Masimo to post 4.47 earnings per share for the current year.

Masimo Institutional Trading

Several hedge funds and other institutional investors have recently changed their positions in MASI. Brown Advisory Inc. increased its position in Masimo shares by 55.9% in the second quarter. Brown Advisory Inc. now owns 15,542 shares of the medical equipment supplier valued at $2,031,000 after acquiring an additional 5,575 shares last quarter. M&G Investment Management Ltd. increased its position in Masimo by 11.1% in the second quarter. M&G Investment Management Ltd. now owns 1,631 shares of the medical equipment supplier valued at $214,000 after buying an additional 163 shares in the last quarter. ExodusPoint Capital Management LP increased its stake in Masimo shares by 106.4% in the second quarter. ExodusPoint Capital Management LP now owns 45,063 shares of the medical equipment supplier worth $5,888,000 after buying 23,226 additional shares in the last quarter. Goldman Sachs Group Inc. increased its stake in Masimo to 92.1% during the second quarter. Goldman Sachs Group Inc. now owns 856,664 shares of the medical equipment supplier worth $111,940,000 after buying an additional 410,793 shares in the last quarter. Finally, Nomura Holdings Inc. purchased a new Masimo stock position in Q2 for a value of approximately $242,537,000. Institutional investors and hedge funds hold 93.31% of the company’s shares.

Masimo Company Profile

(Get an evaluation)

Masimo Corporation develops, manufactures and markets noninvasive monitoring technologies and hospital automation solutions worldwide. Company offers pulse oximetry based on Masimo Signal Extraction Technology (SET) with measurement through motion and low perfusion pulse oximetry monitoring to address key limitations of conventional pulse oximetry .

Featured articles

The Fly logo

Analyst Recommendations for Masimo (NASDAQ: MASI)

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Masimo, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Masimo wasn’t on the list.

While Masimo currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Eleanor C. William